Corbus Pharmaceuticals Holdings Company Profile (NASDAQ:CRBP)

About Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings logoCorbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's product, JBT-101, is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. JBT-101 stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing JBT-101 to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CRBP
  • CUSIP: N/A
  • Web: www.corbuspharma.com
Capitalization:
  • Market Cap: $323.91 million
  • Outstanding Shares: 50,218,000
Average Prices:
  • 50 Day Moving Avg: $6.61
  • 200 Day Moving Avg: $7.68
  • 52 Week Range: $2.62 - $10.78
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.77
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $2.81 million
  • Price / Sales: 115.27
  • Book Value: $0.87 per share
  • Price / Book: 7.41
Profitability:
  • EBIDTA: ($24,450,000.00)
  • Net Margins: -785.22%
  • Return on Equity: -128.85%
  • Return on Assets: -90.84%
Debt:
  • Current Ratio: 2.99%
  • Quick Ratio: 2.99%
Misc:
  • Average Volume: 1.12 million shs.
  • Beta: 2.43
  • Short Ratio: 4.72
 

Frequently Asked Questions for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

What is Corbus Pharmaceuticals Holdings' stock symbol?

Corbus Pharmaceuticals Holdings trades on the NASDAQ under the ticker symbol "CRBP."

How were Corbus Pharmaceuticals Holdings' earnings last quarter?

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) posted its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.16) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.16). The business had revenue of $1.29 million for the quarter, compared to analysts' expectations of $2.50 million. Corbus Pharmaceuticals Holdings had a negative return on equity of 128.85% and a negative net margin of 785.22%. View Corbus Pharmaceuticals Holdings' Earnings History.

Where is Corbus Pharmaceuticals Holdings' stock going? Where will Corbus Pharmaceuticals Holdings' stock price be in 2017?

4 brokers have issued 1-year price objectives for Corbus Pharmaceuticals Holdings' shares. Their predictions range from $12.00 to $27.00. On average, they expect Corbus Pharmaceuticals Holdings' stock price to reach $20.50 in the next year. View Analyst Ratings for Corbus Pharmaceuticals Holdings.

Are investors shorting Corbus Pharmaceuticals Holdings?

Corbus Pharmaceuticals Holdings saw a increase in short interest in the month of April. As of April 28th, there was short interest totalling 6,683,963 shares, an increase of 1.0% from the April 13th total of 6,620,845 shares. Based on an average daily trading volume, of 799,776 shares, the days-to-cover ratio is currently 8.4 days.

Who are some of Corbus Pharmaceuticals Holdings' key competitors?

Who are Corbus Pharmaceuticals Holdings' key executives?

Corbus Pharmaceuticals Holdings' management team includes the folowing people:

  • Mark A. Tepper Ph.D., President, Chief Scientific Officer
  • Yuval Cohen Ph.D., Chief Executive Officer, Director
  • Sean F. Moran CPA, Chief Financial Officer
  • Barbara White M.D., Chief Medical Officer
  • David P Hochman, Director
  • Avery W. Catlin CPA, Independent Director
  • Renu Gupta M.D., Independent Director
  • Alan F. Holmer J.D., Independent Director

Who owns Corbus Pharmaceuticals Holdings stock?

Corbus Pharmaceuticals Holdings' stock is owned by a number of of retail and institutional investors. Top institutional investors include KNOLL CAPITAL MANAGEMENT, LP (7.30%), STERN ADAM K (4.90%), Vanguard Group Inc. (2.58%), Perceptive Advisors LLC (2.57%), FMR LLC (1.94%) and Raymond James Financial Services Advisors Inc. (0.83%). Company insiders that own Corbus Pharmaceuticals Holdings stock include Alan F Holmer, Avery W Catlin, Barbara White, David P Hochman, Renu Gupta, Sean F Moran, Sumner Burstein and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals Holdings.

Who sold Corbus Pharmaceuticals Holdings stock? Who is selling Corbus Pharmaceuticals Holdings stock?

Corbus Pharmaceuticals Holdings' stock was sold by a variety of institutional investors in the last quarter, including EAM Investors LLC, FMR LLC, Private Advisor Group LLC and Perceptive Advisors LLC. View Insider Buying and Selling for Corbus Pharmaceuticals Holdings.

Who bought Corbus Pharmaceuticals Holdings stock? Who is buying Corbus Pharmaceuticals Holdings stock?

Corbus Pharmaceuticals Holdings' stock was purchased by a variety of institutional investors in the last quarter, including KCG Holdings Inc., Laurion Capital Management LP, Vanguard Group Inc., Segantii Capital Management Ltd, BlueCrest Capital Management Ltd, Geode Capital Management LLC, Morgan Stanley and Raymond James Financial Services Advisors Inc.. Company insiders that have bought Corbus Pharmaceuticals Holdings stock in the last two years include Alan F Holmer, Avery W Catlin, Barbara White, David P Hochman, Renu Gupta, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals Holdings.

How do I buy Corbus Pharmaceuticals Holdings stock?

Shares of Corbus Pharmaceuticals Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corbus Pharmaceuticals Holdings' stock price today?

One share of Corbus Pharmaceuticals Holdings stock can currently be purchased for approximately $6.45.


MarketBeat Community Rating for Corbus Pharmaceuticals Holdings (NASDAQ CRBP)
Community Ranking:  4.9 out of 5 (   )
Outperform Votes:  76 (Vote Outperform)
Underperform Votes:  1 (Vote Underperform)
Total Votes:  77
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.50 (217.83% upside)

Analysts' Ratings History for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/14/2017Noble FinancialReiterated RatingBuyLowView Rating Details
5/9/2017Cantor FitzgeraldSet Price TargetBuy$24.00MediumView Rating Details
4/3/2017JMP SecuritiesReiterated RatingOutperform$20.00 -> $27.00LowView Rating Details
11/30/2016AegisReiterated RatingBuy$12.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Earnings by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Earnings History by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.16)($0.16)$2.50 million$1.29 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.12)($0.18)$1.50 million$0.38 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.10)($0.12)$1.00 million$0.74 millionViewN/AView Earnings Details
8/15/2016Q216($0.08)($0.11)$1.25 million$0.40 millionViewN/AView Earnings Details
5/16/2016Q116($0.08)($0.08)$0.40 millionViewN/AView Earnings Details
11/10/2015Q315($0.08)($0.06)$0.17 millionViewN/AView Earnings Details
8/13/2015Q2 2015($0.06)($0.10)$0.11 millionViewN/AView Earnings Details
2/10/2015Q4 2014($0.03)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Current Year EPS Consensus Estimate: $-0.77 EPS
Next Year EPS Consensus Estimate: $-0.66 EPS

Dividends

Dividend History for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Insider Ownership Percentage: 11.60%
Institutional Ownership Percentage: 25.91%
Insider Trades by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Institutional Ownership by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Insider Trades by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/11/2017Barbara WhiteInsiderBuy2,435$6.12$14,902.20View SEC Filing  
5/11/2017David P HochmanDirectorBuy3,400$6.18$21,012.00View SEC Filing  
5/11/2017Sean F MoranCFOBuy3,300$6.14$20,262.00View SEC Filing  
5/11/2017Yuval CohenCEOBuy3,250$6.01$19,532.50View SEC Filing  
3/17/2017Barbara WhiteInsiderBuy4,233$9.49$40,171.17View SEC Filing  
3/13/2017Sean F MoranCFOBuy2,000$9.60$19,200.00View SEC Filing  
12/2/2016Sean F MoranCFOBuy1,500$7.20$10,800.00View SEC Filing  
11/22/2016Alan F HolmerDirectorBuy1,000$7.49$7,490.00View SEC Filing  
11/22/2016Yuval CohenCEOBuy1,340$7.64$10,237.60View SEC Filing  
11/18/2016David P HochmanDirectorBuy10,000$7.00$70,000.00View SEC Filing  
9/8/2016Sean F MoranCFOBuy30,800$5.12$157,696.00View SEC Filing  
8/26/2016Sean F MoranCFOBuy17,900$3.92$70,168.00View SEC Filing  
8/22/2016David P HochmanDirectorBuy1,800$3.77$6,786.00View SEC Filing  
8/18/2016Sean F MoranCFOBuy148,960$3.32$494,547.20View SEC Filing  
8/17/2016Barbara WhiteInsiderBuy38,000$3.15$119,700.00View SEC Filing  
6/8/2016Barbara WhiteInsiderBuy1,935$3.10$5,998.50View SEC Filing  
6/6/2016Yuval CohenCEOBuy1,500$3.34$5,010.00View SEC Filing  
6/1/2016Barbara WhiteInsiderBuy2,570$3.52$9,046.40View SEC Filing  
5/19/2016Sean F MoranCFOBuy27,250$2.37$64,582.50View SEC Filing  
5/18/2016Sean F MoranCFOBuy30,000$2.39$71,700.00View SEC Filing  
5/18/2016Yuval CohenCEOBuy2,125$2.40$5,100.00View SEC Filing  
12/11/2015Sean F MoranCFOBuy1,000$1.56$1,560.00View SEC Filing  
12/10/2015Sean F MoranCFOBuy1,000$1.61$1,610.00View SEC Filing  
12/9/2015Sean F MoranCFOBuy1,000$1.67$1,670.00View SEC Filing  
12/8/2015Sean F MoranCFOBuy1,000$1.68$1,680.00View SEC Filing  
12/7/2015Sean F MoranCFOBuy1,000$1.69$1,690.00View SEC Filing  
12/4/2015Sean F MoranCFOBuy1,000$1.72$1,720.00View SEC Filing  
12/2/2015Sean F MoranCFOBuy1,000$1.79$1,790.00View SEC Filing  
11/24/2015Sean F MoranCFOBuy1,500$1.78$2,670.00View SEC Filing  
11/20/2015Sean F MoranCFOBuy1,500$1.70$2,550.00View SEC Filing  
11/19/2015Barbara WhiteInsiderBuy4,000$1.67$6,680.00View SEC Filing  
11/18/2015Sean F MoranCFOBuy1,500$1.71$2,565.00View SEC Filing  
11/17/2015Sean F MoranCFOBuy1,500$1.72$2,580.00View SEC Filing  
11/16/2015Sean F MoranCFOBuy2,000$1.69$3,380.00View SEC Filing  
9/16/2015Sean F MoranCFOBuy5,000$2.12$10,600.00View SEC Filing  
9/15/2015Sean F MoranCFOBuy5,000$2.14$10,700.00View SEC Filing  
9/14/2015Sean F MoranCFOBuy5,000$1.96$9,800.00View SEC Filing  
9/11/2015Sean F MoranCFOBuy5,000$1.85$9,250.00View SEC Filing  
9/3/2015Barbara WhiteInsiderBuy10,000$1.84$18,400.00View SEC Filing  
8/25/2015Barbara WhiteInsiderBuy6,000$1.87$11,220.00View SEC Filing  
8/21/2015Barbara WhiteInsiderBuy10,000$2.05$20,500.00View SEC Filing  
8/21/2015Sean F MoranCFOBuy1,400$2.06$2,884.00View SEC Filing  
8/19/2015Sumner BursteinMajor ShareholderSell200,000$3.04$608,000.00View SEC Filing  
8/18/2015Barbara WhiteinsiderBuy20,000$1.90$38,000.00View SEC Filing  
8/18/2015Renu GuptaDirectorBuy10,000$1.89$18,900.00View SEC Filing  
8/18/2015Sean F MoranCFOBuy1,000$1.92$1,920.00View SEC Filing  
8/17/2015Avery W CatlinDirectorBuy11,788$1.94$22,868.72View SEC Filing  
8/17/2015Yuval CohenCEOBuy2,100$1.92$4,032.00View SEC Filing  
7/15/2015Sumner BursteinMajor ShareholderSell30,000$2.82$84,600.00View SEC Filing  
6/15/2015Barbara WhiteInsiderBuy2,250$3.25$7,312.50View SEC Filing  
6/12/2015Barbara WhiteInsiderBuy6,000$3.00$18,000.00View SEC Filing  
6/9/2015Avery W CatlinDirectorBuy20,000$3.10$62,000.00View SEC Filing  
6/9/2015Sean F MoranCFOBuy6,500$3.00$19,500.00View SEC Filing  
12/18/2014Sean F MoranCFOBuy18,800$3.36$63,168.00View SEC Filing  
12/17/2014Sean F MoranCFOBuy2,850$3.46$9,861.00View SEC Filing  
12/11/2014Sean F MoranCFOBuy1,000$3.98$3,980.00View SEC Filing  
12/9/2014Sean F MoranCFOBuy1,700$3.98$6,766.00View SEC Filing  
12/4/2014Barbara WhiteInsiderBuy3,300$3.00$9,900.00View SEC Filing  
12/4/2014David P HochmanDirectorBuy1,300$3.05$3,965.00View SEC Filing  
12/4/2014Sean F MoranCFOBuy2,000$3.20$6,400.00View SEC Filing  
12/3/2014Yuval CohenCEOBuy1,000$3.20$3,200.00View SEC Filing  
12/2/2014Sean F MoranCFOBuy1,000$3.03$3,030.00View SEC Filing  
12/1/2014Barbara WhiteInsiderBuy16,448$3.00$49,344.00View SEC Filing  
11/28/2014Barbara WhiteInsiderBuy19,933$3.00$59,799.00View SEC Filing  
11/26/2014Barbara WhiteInsiderBuy13,400$3.00$40,200.00View SEC Filing  
11/26/2014Sean F MoranCFOBuy1,000$3.05$3,050.00View SEC Filing  
11/25/2014Mark TepperInsiderBuy2,000$3.05$6,100.00View SEC Filing  
11/25/2014Sean F MoranCFOBuy3,000$3.05$9,150.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Latest Headlines for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 4:19 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings Inc (CRBP) Short Interest Update
www.americanbankingnews.com - May 22 at 2:46 PM
finance.yahoo.com logoTop 4 Marijuana Stocks to Watch for 2017
finance.yahoo.com - May 18 at 4:24 PM
americanbankingnews.com logoNoble Financial Reiterates Buy Rating for Corbus Pharmaceuticals Holdings Inc (CRBP)
www.americanbankingnews.com - May 14 at 8:45 AM
americanbankingnews.com logoInsider Buying: Corbus Pharmaceuticals Holdings Inc (CRBP) Director Purchases 3,400 Shares of Stock
www.americanbankingnews.com - May 12 at 4:46 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings Inc (CRBP) CFO Sean F. Moran Buys 3,300 Shares
www.americanbankingnews.com - May 12 at 4:46 PM
americanbankingnews.com logoInsider Buying: Corbus Pharmaceuticals Holdings Inc (CRBP) Insider Buys 2,435 Shares of Stock
www.americanbankingnews.com - May 12 at 10:17 AM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings Inc (CRBP) CEO Yuval Cohen Purchases 3,250 Shares
www.americanbankingnews.com - May 12 at 10:16 AM
streetinsider.com logoCorbus Pharma (CRBP) Says Last Subject Enrolled in Phase 2 Study of Anabasum - StreetInsider.com
www.streetinsider.com - May 11 at 5:07 PM
finance.yahoo.com logoCorbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Anabasum for the Treatment of Skin-Predominant Dermatomyositis
finance.yahoo.com - May 11 at 5:07 PM
finance.yahoo.com logoCorbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Anabasum for the Treatment of Skin-Predominant Dermatomyositis
finance.yahoo.com - May 11 at 5:07 PM
finance.yahoo.com logoETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 5:07 PM
finance.yahoo.com logoETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 5:07 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings Inc (CRBP) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 12:04 AM
finance.yahoo.com logoCorbus Pharmaceuticals Holdings, Inc. :CRBP-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 4:41 PM
finance.yahoo.com logoToday's Research Reports on Corbus Pharmaceuticals and Pluristem Therapeutics Post Earnings
finance.yahoo.com - May 10 at 8:10 AM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings Inc (CRBP) PT Set at $24.00 by Cantor Fitzgerald
www.americanbankingnews.com - May 9 at 11:36 PM
finance.yahoo.com logoCorbus Pharmaceuticals Reports 2017 First Quarter Financial Results and Provides Business Update
finance.yahoo.com - May 9 at 4:29 PM
marketbeat.com logoCorbus Pharmaceuticals reports 1Q loss
marketbeat.com - May 9 at 9:22 AM
prnewswire.com logoThe Creation of Jobs in the Legal Cannabis Market
www.prnewswire.com - May 5 at 4:41 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings (CRBP) Earning Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - May 4 at 1:15 AM
finance.yahoo.com logoRead This Before You Buy Biotech Stocks
finance.yahoo.com - May 1 at 8:25 AM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings (CRBP) Getting Positive News Coverage, Study Finds
www.americanbankingnews.com - April 27 at 7:26 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings (CRBP) Earning Somewhat Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 23 at 5:07 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings (CRBP) Given Daily Coverage Optimism Rating of 0.23
www.americanbankingnews.com - April 20 at 4:52 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings (CRBP) Earns Media Sentiment Rating of 0.24
www.americanbankingnews.com - April 14 at 9:22 AM
prnewswire.com logoResearch Reports Initiation on Biotech Stocks -- Tesaro, Alnylam Pharma, Corbus Pharma, and Inovio Pharma - PR Newswire (press release)
www.prnewswire.com - April 12 at 8:18 AM
finance.yahoo.com logoDid Corbus Investors Get Thrown Off by a Red Herring?
finance.yahoo.com - April 10 at 4:20 PM
finance.yahoo.com logoWhat's Next for Corbus Pharmaceuticals After Its Controversial Cystic Fibrosis Results?
finance.yahoo.com - April 8 at 4:23 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings Inc (CRBP) Rating Reiterated by Noble Financial
www.americanbankingnews.com - April 8 at 8:06 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Corbus Pharmaceuticals Holdings, Inc.
finance.yahoo.com - April 7 at 4:27 PM
finance.yahoo.com logoCorbus Pharmaceuticals to Commence Single Phase 3 Study of Anabasum for Treatment of Systemic Sclerosis Following Guidance Received from Successful End-of-Phase 2 Meeting with FDA
finance.yahoo.com - April 7 at 9:10 AM
finance.yahoo.com logoCorbus says anti-inflammatory drug will enter late-stage trial this year
finance.yahoo.com - April 7 at 9:10 AM
finance.yahoo.com logoCorbus Gets FDA Green Light for Phase 3 Drug Study
finance.yahoo.com - April 7 at 9:10 AM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings' (CRBP) Buy Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - April 5 at 2:13 PM
americanbankingnews.com logoZacks: Analysts Set $18.75 Target Price for Corbus Pharmaceuticals Holdings Inc (CRBP)
www.americanbankingnews.com - April 4 at 12:01 AM
americanbankingnews.com logoJMP Securities Reiterates "Outperform" Rating for Corbus Pharmaceuticals Holdings Inc (CRBP)
www.americanbankingnews.com - April 3 at 1:18 PM
seekingalpha.com logoA Long Way For Corbus Pharma Cystic Fibrosis Drug
seekingalpha.com - March 31 at 4:37 PM
capitalcube.com logoCorbus Pharmaceuticals Holdings, Inc. breached its 50 day moving average in a Bearish Manner : CRBP-US : March 31, 2017
us.rd.yahoo.com - March 31 at 4:37 PM
streetinsider.com logoCorbus Pharma (CRBP) Reports Positive Topline Ph2 Data for Multiple Doses of Anabasum (fka JBT-101 or Resunab) for the Treatment of Cystic Fibrosis
www.streetinsider.com - March 31 at 2:56 AM
us.rd.yahoo.com logoCorbus Pharmaceuticals Reports Positive Topline Data Demonstrating Anabasum Reduces Acute Pulmonary Exacerbations and Multiple Inflammatory Biomarkers in Phase 2 Study in Patients with Cystic Fibrosis
us.rd.yahoo.com - March 30 at 4:54 PM
biz.yahoo.com logoCORBUS PHARMACEUTICALS HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statement
us.rd.yahoo.com - March 30 at 4:54 PM
us.rd.yahoo.com logoBlog Coverage Acorda Reported Long-term Safety Data
us.rd.yahoo.com - March 30 at 4:54 PM
thestreet.com logoCorbus Pharma Drug Shows No Clinical Benefit for Cystic Fibrosis Patients
us.rd.yahoo.com - March 30 at 4:54 PM
us.rd.yahoo.com logoCorbus Pharma Add-on Drug Clears Mid-Stage Study
us.rd.yahoo.com - March 30 at 4:54 PM
fool.com logoWhy "Positive" Data Knocked Down Corbus Pharmaceuticals Holdings Inc Today
www.fool.com - March 30 at 1:35 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings Inc (CRBP) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - March 30 at 11:25 AM
finance.yahoo.com logoBiotech Coverage After the Collapse of Trumpcare: Today's Research Reports on Cara Therapeutics and Corbus Pharmaceuticals
finance.yahoo.com - March 28 at 12:27 PM
americanbankingnews.com logoResearch Analysts Offer Predictions for Corbus Pharmaceuticals Holdings Inc's FY2017 Earnings (CRBP)
www.americanbankingnews.com - March 23 at 9:44 AM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings Inc (CRBP) Insider Barbara White Purchases 4,233 Shares
www.americanbankingnews.com - March 20 at 1:33 PM

Social

Chart

Corbus Pharmaceuticals Holdings (CRBP) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff